In line with the reported oncogenic role of FTO demethylase in a subset of AMLs [90] and the anti-tumor effect exerted by an FTO inhibitor (R-2HG) [92], Huang et al. [104] utilized structure-guided design to optimize Meclofenamic acid (MA), a previously identified FTO inhibitor [91]. This evidence concerns the gene FTO and neoplasm.